Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (131-140 of 361) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapySusan Halabi, Andrew J Armstrong, Oliver Sartor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castrationOren Smaletz, Howard I Scher, Eric J Small, et al.
Prostate Cancer and Prostatic Diseases|April 15, 2020
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancerRahul Aggarwal, Gustavo Rubio Romero, Verena Friedl, et al.
BJU International|June 27, 2006
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin, Brian I Rini, Vivian Weinberg, et al.
BJU International|July 11, 2006
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene statusBrian I Rini, Erich Jaeger, Vivian Weinberg, et al.
Urologic Oncology|March 14, 2007
Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancerCharles J Ryan, Christopher M Haqq, Jeffrey Simko, et al.
Cancer|April 6, 2021
Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortalityDanielle S Bitterman, Ming-Hui Chen, Jing Wu, et al.
The Journal of Urology|March 29, 2021
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance)James A Eastham, Glenn Heller, David W Hillman, et al.
Contemporary Clinical Trials|October 6, 2015
Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patientsCelia P Kaplan, Anna Maria Nápoles, Steven Narine, et al.
Cancer|December 22, 2017
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trialsKatelyn M Atkins, Ming-Hui Chen, Jing Wu, et al.
Pageof 37

Showing results (131-140 of 361) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapySusan Halabi, Andrew J Armstrong, Oliver Sartor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castrationOren Smaletz, Howard I Scher, Eric J Small, et al.
Prostate Cancer and Prostatic Diseases|April 15, 2020
Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancerRahul Aggarwal, Gustavo Rubio Romero, Verena Friedl, et al.
BJU International|June 27, 2006
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin, Brian I Rini, Vivian Weinberg, et al.
BJU International|July 11, 2006
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene statusBrian I Rini, Erich Jaeger, Vivian Weinberg, et al.
Urologic Oncology|March 14, 2007
Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancerCharles J Ryan, Christopher M Haqq, Jeffrey Simko, et al.
Cancer|April 6, 2021
Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortalityDanielle S Bitterman, Ming-Hui Chen, Jing Wu, et al.
The Journal of Urology|March 29, 2021
Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance)James A Eastham, Glenn Heller, David W Hillman, et al.
Contemporary Clinical Trials|October 6, 2015
Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patientsCelia P Kaplan, Anna Maria Nápoles, Steven Narine, et al.
Cancer|December 22, 2017
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trialsKatelyn M Atkins, Ming-Hui Chen, Jing Wu, et al.
Pageof 37